Why Focus on Stroke in People With Type 2 Diabetes?

*The CME/CE credit for the educational activity is expired.*  Description In this CME/CE module, Karen Furie outlines the relationship between type 2 diabetes and stroke, and describes the importance of strategies to reduce stroke risk in this population. This activity features a series of 6 video episodes. This series of independent, accredited continuing education activities is designed for healthcare professionals involved in the care of individuals with type 2 diabetes, particularly primary care practitioners, endocrinologists, and neurologists. The aim of the program is to educate the intended audience on the increased risk for stroke in people with type 2 diabetes and how to reduce this risk. The series will cover data on the type 2 diabetes drugs that have been linked to stroke risk reduction, namely glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and pioglitazone, along with guideline recommendations for their use. Experts will discuss best-practice approaches for the use of GLP-1 RAs to reduce stroke risk in this population, including choice of GLP-1 RA, dosing, mode of administration, use in combination with other therapies, when to adapt therapy, and avoidance and management of side effects. Learning Objectives Upon completion of this activity, learners will be able to: • Describe the association between T2D and stroke, and the need for early use of appropriate interventions by multiple HCPs to reduce risk • Discuss the role of GLP-1 RAs in reducing stroke risk among people with T2D as part of a comprehensive treatment strategy • Implement the use of GLP-1 RAs with proven cardiovascular benefit to reduce the risk of stroke in individuals with T2D, according to evidence-based recommendations Faculty Karen L Furie, MD, MPH Chief of Neurology Rhode Island Hospital Providence, RI United States Faculty and Staff Disclosures and Mitigation of Relevant Financial Interests It is the policy of IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, faculty, CME/CE provider staff, and educational partner staff) are expected to disclose any relevant financial relationships with ineligible companies over the past 24 months. It is also required that faculty identify and reference off-label products or investigational uses of pharmaceutical agents and medical devices. IMNE utilizes a peer review process to mitigate potential and actual conflicts of interest disclosed by all persons in a position to influence the planning process or content development of this educational activity. All peer reviewers are without relevant financial relationships. A copy of the mitigation worksheet is available by request from [email protected]. The following disclosures have been made: Faculty Karen L Furie, MD, MPH Consultant or advisor for: Janssen/BMS Librexia IMNE Staff Steve Weinman, MSc, RN Director of Accreditation ANCC Accredited Provider Program Director Mr Weinman has nothing to disclose Amy Groves, BS (With Honors) Business Lead Ms Groves has nothing to disclose Ruth Wills, PhD Scientific Director Dr Wills has nothing to disclose Elena Pinceti, PhD Associate Program Director Dr Pinceti has nothing to disclose Claire Barnard, PhD Editorial Team Leader Dr Barnard has nothing to disclose Michelle Fisher, BS Account Coordinator Ms Fisher has nothing to disclose CME Peer Reviewer Martin Quan, MD Dr Quan has nothing to disclose Commercial Support Acknowledgment This activity is supported by an educational grant from Novo Nordisk, Inc.